HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Differential responses of myeloid progenitor cells from patients with myeloid leukemia and myelodysplasia to the costimulating effects of steel factor in vitro.

Abstract
Steel factor (SLF, c-kit ligand), a potent costimulating cytokine in vitro for myeloid progenitor cells from normal donors, is currently being evaluated in clinical trials for effects on hematopoiesis. Based on a preliminary observation that colony-stimulating factor (CSF)-responsive myeloid progenitor cells (CFU-GM) from a few patients with acute myeloid leukemia (AML) did not respond to the costimulating effects of SLF, we evaluated responsiveness of bone marrow or blood CFU-GM from 26 patients with either AML, chronic myeloid leukemia (CML) or myelodysplastic syndrome (MDS) to the effects in vitro of SLF and/or granulocyte-macrophage CSF (GM-CSF). Cells from all 26 patients responded to the stimulating effects of GM-CSF, but marked heterogeneity was detected in each disease category to the costimulating effects of SLF. Nine of 13 patients with AML, 2 of 6 patients with CML and 4 of 7 patients with MDS had clonogenic cells that did not respond significantly to the costimulating effects of SLF. In a more limited study of cells from patients with MDS, it was noted that if the CFU-GM of that patient did not respond to SLF enhancement of CSF-induced colony formation, neither did the erythropoietin (Epo)-dependent erythroid (BFU-E) or multipotential (CFU-GEMM) cells of that patient (3 cases of refractory anemia [RA] evaluating bone marrow and in 1 case blood progenitors as well). If CFU-GM responded, BFU-E and CFU-GEMM responded (bone marrow from 1 patient with chronic myelomonocytic leukemia [CMMol]). Clinical criteria did not readily distinguish between patients who had SLF-responsive vs. -nonresponsive clonogenic cells. While the mechanistic reason for this heterogeneity in responsiveness is not clear, these differences should be carefully considered for possible clinical trials with SLF in patients with acute and chronic myeloid leukemia and MDS.
AuthorsR Maze, M Horie, P Hendrie, S Vadhan-Raj, G Tricot, M Gordon, J Nemunaitis, L K Ashman, H E Broxmeyer
JournalExperimental hematology (Exp Hematol) Vol. 21 Issue 4 Pg. 545-51 (Apr 1993) ISSN: 0301-472X [Print] UNITED STATES
PMID7681784 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Hematopoietic Cell Growth Factors
  • Recombinant Proteins
  • Stem Cell Factor
  • Granulocyte-Macrophage Colony-Stimulating Factor
Topics
  • Adult
  • Aged
  • Cells, Cultured
  • Colony-Forming Units Assay
  • Granulocyte-Macrophage Colony-Stimulating Factor (pharmacology)
  • Hematopoiesis (drug effects)
  • Hematopoietic Cell Growth Factors (pharmacology)
  • Hematopoietic Stem Cells (drug effects)
  • Humans
  • In Vitro Techniques
  • Leukemia, Myeloid (pathology)
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes (pathology)
  • Recombinant Proteins (pharmacology)
  • Stem Cell Factor

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: